This is a preview of subscription content, log in via an institution to check access.
Notes
Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Reference
Loong HH, et al. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. PharmacoEconomics-Open : 17 Sep 2019. Available from: URL: https://doi.org/10.1007/s41669-019-00178-7
Rights and permissions
About this article
Cite this article
Pembrolizumab for PD-L1+ NSCLC cost effective in Hong Kong. PharmacoEcon Outcomes News 838, 22 (2019). https://doi.org/10.1007/s40274-019-6267-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6267-x